Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
BMC Infectious Diseases|May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trialXavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
The Journal of Infectious Diseases|October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observationAnne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
The Journal of Infectious Diseases|March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIAXavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
The Lancet. Oncology|June 14, 2015
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA TrialsAimée R Kreimer, Frank Struyf, Maria Rowena Del Rosario-Raymundo, et al.
Pageof 3